OPTIMIZE-1
ET20000214
OPTIMIZE-1: Ph Ib/II_mitazalimab + mFolfirinox_K pancréas méta non résécable
Description of the study :
OPTIMIZE-1 : A phase 1b/2, open-label, multi-center study assessing the clinical efficacy of Mitazalimab in combination with mFOLFIRINOX in unresectable and metastatic pancreatic cancer.
Coordinating doctor : Dr CASSIER Philippe
Co-investigators : Dr TERRET Catherine ; Dr BRAHMI Mehdi ; Dr SWALDUZ Aurélie ; Dr VINCENEUX Armelle ; Dr VANACKER Hélène ;
Promoter : ALLIGATOR BIOSCIENCE AB
Treatment type : 01 - Chimiothérapie / Thérapie ciblée ;